Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis

被引:5
|
作者
Anderson, Kathryn L. [1 ]
Feldman, Steven R. [1 ,2 ,3 ]
机构
[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27157 USA
[3] Wake Forest Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA
关键词
psoriasis; phototherapy; dermatology; TREATMENT PATTERNS; DRUG SURVIVAL; BIOLOGICS; DISCONTINUATION; POPULATION; ETANERCEPT; ADALIMUMAB; CARE; IMPAIRMENT; THERAPIES;
D O I
10.1177/1203475415572797
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis treatment involves multiple treatment arms. Treatment choice depends on many factors and may change, due to the chronicity of psoriasis. Objective: The purpose of our study is to explore reasons for treatment changes in patients with moderate to severe psoriasis. Methods: Ten charts of patients with moderate to severe psoriasis were reviewed. The medication changes and reasons for change were extracted. A treatment change was defined as switching between medication classes, adding or removing a medication class, or switching medications within the oral or biologic medication class. Results: Seventy-seven treatment changes were identified. On average, I treatment change occurred per year of follow-up. The most common reason for treatment change was inadequate disease control. Conclusions: Inadequate disease control with current therapy is the most common reason a physician changes treatment for moderate to severe psoriasis. More efficacious treatments or ways to improve efficacy may help improve the long-term outcomes of psoriasis.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [31] Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
    Mastorino, Luca
    Siliquini, Niccolo
    Avallone, Gianluca
    Ortoncelli, Michela
    Quaglino, Pietro
    Dapavo, Paolo
    Ribero, Simone
    DERMATOLOGY REPORTS, 2022, 14 (03)
  • [32] Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis
    Talamonti, M.
    Galluzzo, M.
    Teoli, M.
    Bavetta, M.
    Chimenti, S.
    Costanzo, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E34 - E34
  • [33] Etanercept treatment is able to modulate apoptosis process in patients with moderate to severe psoriasis
    Lembo, Serena
    Megna, Matteo
    Caiazzo, Giuseppina
    Ayala, Fabio
    Balato, Nicola
    Balato, Anna
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB30 - AB30
  • [34] TREATMENT SATISFACTION AMONG PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN BRAZIL
    Lopes, N.
    Suarez, R. M.
    Sabbag, C. Y.
    Kobata, C. M.
    Takemoto, M. S.
    Pertel, P.
    VALUE IN HEALTH, 2017, 20 (09) : A902 - A902
  • [35] The Treatment of Moderate-to-Severe Psoriasis: Prescreening and Monitoring Psoriatic Patients on Biologics
    Levine, Danielle
    Strober, Bruce E.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2010, 29 (01) : 28 - 34
  • [36] Treatment patterns in moderate to severe plaque psoriasis patients with multiple biologic failures
    Gulliver, Wayne
    Gulliver, Susanne R.
    DiBattista, Michelle
    Power, Rebecca
    Green, Rebecca
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB141 - AB141
  • [37] Efficacy and safety of infliximab biosimilars in the treatment of patients with moderate-to-severe psoriasis
    Chasapi, Vasiliki
    Routsi, Eleni
    Lantzou, Sotiria
    Papoutsaki, Marina
    Panagakis, Pantelis
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [38] TREATMENT OF PATIENTS WITH MODERATE AND SEVERE PSORIASIS - COST-OF-ILLNESS IN THE CZECH REPUBLIC
    Petrikova, A.
    Klimes, J.
    Dolezal, T.
    Marinov, L.
    Petrova, G.
    VALUE IN HEALTH, 2011, 14 (07) : A305 - A306
  • [39] Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation
    Ruggiero, Angelo
    Potestio, Luca
    Martora, Fabrizio
    Villani, Alessia
    Comune, Rosita
    Megna, Matteo
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (05) : 355 - 362
  • [40] Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan
    Tada, Yayoi
    Soliman, Ahmed M.
    Ishii, Kanako
    Sakuma, Ryuta
    Pinter, Andreas
    Davis, Matthew
    Nunag, Dominic
    Buessing, Marric
    Puig, Luis
    Imafuku, Shinichi
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (05)